83 related articles for article (PubMed ID: 34145699)
1. Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model.
Ohkawa Y; Zhang P; Momota H; Kato A; Hashimoto N; Ohmi Y; Bhuiyan RH; Farhana Y; Natsume A; Wakabayashi T; Furukawa K; Furukawa K
Cancer Sci; 2021 Sep; 112(9):3756-3768. PubMed ID: 34145699
[TBL] [Abstract][Full Text] [Related]
2. GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior.
Bhat AM; Mohapatra BC; Luan H; Mushtaq I; Chakraborty S; Kumar S; Wu W; Nolan B; Dutta S; Storck MD; Schott M; Meza JL; Lele SM; Lin MF; Cook LM; Corey E; Morrissey C; Coulter DW; Rowley MJ; Natarajan A; Datta K; Band V; Band H
Sci Rep; 2024 Jun; 14(1):13523. PubMed ID: 38866755
[TBL] [Abstract][Full Text] [Related]
3. Targeting NFκB signaling in GD2
Nguyen K; Battula VL
Aging (Albany NY); 2017 Aug; 9(8):1847-1848. PubMed ID: 28858852
[No Abstract] [Full Text] [Related]
4. Gangliosides in neural stem cell fate determination and nerve cell specification--preparation and administration.
Itokazu Y; Ariga T; Fuchigami T; Li D
bioRxiv; 2024 Jun; ():. PubMed ID: 38915682
[TBL] [Abstract][Full Text] [Related]
5. The cellular origin for malignant glioma and prospects for clinical advancements.
Zong H; Verhaak RG; Canoll P
Expert Rev Mol Diagn; 2012 May; 12(4):383-94. PubMed ID: 22616703
[TBL] [Abstract][Full Text] [Related]
6. GD2 and its biosynthetic enzyme GD3 synthase promote tumorigenesis in prostate cancer by regulating cancer stem cell behavior.
Bhat AM; Mohapatra BC; Luan H; Mushtaq I; Chakraborty S; Kumar S; Wu W; Nolan B; Dutta S; Stock MD; Schott M; Meza JL; Lele SM; Lin MF; Cook LM; Corey E; Morrissey C; Coulter DW; Rowley J; Natarajan A; Datta K; Band V; Band H
bioRxiv; 2024 Apr; ():. PubMed ID: 36993422
[TBL] [Abstract][Full Text] [Related]
7. St8sia1-deficiency in mice alters tumor environments of gliomas, leading to reduced disease severity.
Zhang P; Ohkawa Y; Yamamoto S; Momota H; Kato A; Kaneko K; Natsume A; Farhana Y; Ohmi Y; Okajima T; Bhuiyan RH; Wakabayashi T; Furukawa K; Furukawa K
Nagoya J Med Sci; 2021 Aug; 83(3):535-549. PubMed ID: 34552288
[TBL] [Abstract][Full Text] [Related]
8. Chemoenzymatic Total Synthesis of GM3 Gangliosides Containing Different Sialic Acid Forms and Various Fatty Acyl Chains.
Yu H; Gadi MR; Bai Y; Zhang L; Li L; Yin J; Wang PG; Chen X
J Org Chem; 2021 Jul; 86(13):8672-8682. PubMed ID: 34152144
[TBL] [Abstract][Full Text] [Related]
9. GD3 ganglioside is a promising therapeutic target for glioma patients.
Hein V; Baeza-Kallee N; Bertucci A; Colin C; Tchoghandjian A; Figarella-Branger D; Tabouret E
Neurooncol Adv; 2024; 6(1):vdae038. PubMed ID: 38590763
[TBL] [Abstract][Full Text] [Related]
10. Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers.
Biricioiu MR; Sarbu M; Ica R; Vukelić Ž; Kalanj-Bognar S; Zamfir AD
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279335
[TBL] [Abstract][Full Text] [Related]
11. Glycation Interferes with the Expression of Sialyltransferases and Leads to Increased Polysialylation in Glioblastoma Cells.
Schildhauer P; Selke P; Staege MS; Harder A; Scheller C; Strauss C; Horstkorte R; Scheer M; Leisz S
Cells; 2023 Dec; 12(23):. PubMed ID: 38067186
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors.
Matsumoto Y; Ju T
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509200
[TBL] [Abstract][Full Text] [Related]
13. Recently developed glycosphingolipid probes and their dynamic behavior in cell plasma membranes as revealed by single-molecule imaging.
Suzuki KGN; Komura N; Ando H
Glycoconj J; 2023 Jun; 40(3):305-314. PubMed ID: 37133616
[TBL] [Abstract][Full Text] [Related]
14. Possible regulation of ganglioside GD3 synthase gene expression with DNA methylation in human glioma cells.
Yamamoto Y; Higashimoto K; Ohkawa Y; Soejima H; Kaneko K; Ohmi Y; Furukawa K; Furukawa K
Glycoconj J; 2023 Jun; 40(3):323-332. PubMed ID: 36897478
[TBL] [Abstract][Full Text] [Related]
15. The biological role and immunotherapy of gangliosides and GD3 synthase in cancers.
Cao S; Hu X; Ren S; Wang Y; Shao Y; Wu K; Yang Z; Yang W; He G; Li X
Front Cell Dev Biol; 2023; 11():1076862. PubMed ID: 36824365
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Immunity in the development of anti-cancer drug resistance.
Meng Y; Wang H; Li X; Wu X; Sun H
Front Pharmacol; 2022; 13():1120037. PubMed ID: 36588736
[No Abstract] [Full Text] [Related]
17. Aberrant Sialylation in Cancer: Therapeutic Opportunities.
Munkley J
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077781
[TBL] [Abstract][Full Text] [Related]
18. Gangliosides in nervous system development, regeneration, and pathologies.
Vasques JF; de Jesus Gonçalves RG; da Silva-Junior AJ; Martins RS; Gubert F; Mendez-Otero R
Neural Regen Res; 2023 Jan; 18(1):81-86. PubMed ID: 35799513
[TBL] [Abstract][Full Text] [Related]
19. Signaling domains of cancer-associated glycolipids.
Furukawa K; Ohmi Y; Hamamura K; Kondo Y; Ohkawa Y; Kaneko K; Hashimoto N; Yesmin F; Bhuiyan RH; Tajima O; Furukawa K
Glycoconj J; 2022 Apr; 39(2):145-155. PubMed ID: 35315508
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
